A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma

Gynecologic Oncology

Volumn 93, Issue 1, 2004, Pages 34-40

  Oreskovic, S ^a   Babic, D ^a   Kalafatic, D ^a   Barisic, D ^a   Beketic Oreskovic, L ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Endometrial carcinoma; Estrogen receptor; Ki 67; p53; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN P53; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER SURVIVAL; CHI SQUARE TEST; CONTROLLED STUDY; CURETTAGE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURGICAL TECHNIQUE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842582530     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.12.038     Document Type: Article

References (43)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1996. C.A. Cancer J. Clinic. 46:1996;5-28.
2. Grimes D.A. Diagnostic dilation and curettage: a reappraisal. Am. J. Obstet. Gynecol. 142:1982;1-6.
3. Ehrlich C.E., Young P.C.M., Cleary R.E. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic and carcinomatous endometria: therapeutic implications. Am. J. Obstet. Gynecol. 141:1981;539-545.
4. Palmer D.C., Muir I.M., Alexander A.L., Cauchi M., Bennett R.C., Quin M.A. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet. Gynecol. 72:1988;388-393.
5. Jukic S., Kos M., Gamulin S., Ilic-Forko J., Babic D., Romic Stojkovic R. Steroid hormone receptors in carcinoma of the endometrium: analysis of curettage and hysterectomy samples. Croat. Med. J. 36:1995;30-34.
6. Geisinger K.R., Marschall R.B., Kute T.E., Homesley H.D. Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of endometrium. Cancer. 58:1986;1506-1517.
7. Liao B.S., Twiggs L.B., Leung B.S., Yu W.C.Y., Potish R.A., Prem K.A. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet. Gynecol. 67:1986;463-467.
8. Kleine W., Maier T., Geyer H., Phleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol. Oncol. 38:1990;59-65.
9. Creasman W.T., Soper J.T., McCarty K.S. Jr., McCarty K.S. Sr., Hinshaw W., Clarke-Pearson D.L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am. J. Obstet. Gynecol. 151:1985;922-932.
10. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. Acta Oncol. 28:1989;561-566.
11. Geisinger K.R., Homesley H.D., Morgan T.M., Kute T.E., Marshall R.B. Endometrial adenocarcinoma: a multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer. 58:1986;1518-1525.
12. Kerner H., Sabo E., Friedman M., Beck D., Samare O., Lichting C. A immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of endometrium and the adjacent mucosa. Int. J. Gynecol. Cancer. 5:1995;275-281.
13. Sutton G.P., Geisler H.E., Strehman F.B., Young P.C.M., Kimes T.M., Erlich C.E. Features associated with survival and disease-free survival in early endometrial cancer. Am. J. Obstet. Gynecol. 160:1989;1385-1393.
14. Tornos C., Silva E.G., El-Nagar A., Burke T.W. Aggressive stage I grade 1 endometrial carcinoma. Cancer. 70:1992;790-798.
15. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 71:1993;1467-1470.
16. Kinzler K.W., Vogelstein B. Cancer therapy meets p53. N. Engl. J. Med. 49:1994;331.
17. Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum. Pathol. 29:1998;551-558.
18. Lowe S.W., Ruley H.E., Jacks T. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957.
19. Kounelis C., Kapranos N., Kouri E., Coppola D., Papadaki H., Jones M.W. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod. Path. 13:2000;379-388.
20. Schonk D.M., Kuijpers H.J.H., van Drunen E. Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10. Hum. Genet. 83:1989;297-299.
21. Braun N., Papadopoulos T., Muller-Hermelink H.K. Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells. Virchows Arch. Cell Pathol. 56:1988;25-33.
22. Hall P.A., Levison D.A. Review: assessment of cell proliferation in histological material. J. Clin. Pathol. 43:1990;184-192.
23. Brown D.C., Gatter K.C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 17:1999;489-503.
24. Brown D.C., Cole D., Gatter K.C., Mason D.Y. Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki-67. Br. J. Cancer. 57:1988;178-181.
25. Nielsen A.L., Nyholm H.C.J. Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: comparison of tumors from patients with and without previous oestrogen therapy. J. Pathol. 171:1993;199-205.
26. Aasmundstad T.A., Haugen O.A., Johanssen E., Hoe A.L., Kvinsland S. Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods. J. Clin. Pathol. 45:1992;125-129.
27. Chambers J.T., Carcangiu M.L., Voynick I.M., Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma: Part II. correlation between biochemical and immunohistochemical methods and survival. Am. J. Clin. Pathol. 94:1990;255-260.
28. Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum. Pathol. 29:1998;924-931.
29. Martin J.D., Hahnel R., McCartney T. The effects of estrogen and receptor status on survival in patients with endometrial carcinoma. Am. J. Obstet. Gynecol. 147:1983;322.
30. Creasman W.T., Soper J.T., Mc Carty K.S. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am. J. Obstet. Gynecol. 151:1985;922.
31. Koshiyama M., Konishi I., Wang D.P., Mandai M., Komatsu T., Yamamoto S. et al. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch. A: Pathol. Anat. 423:1993;256-271.
32. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., Heller P.B. Surgical pathologic spread patterns of endometrial cancer. Cancer. 60:1987;2035-2041.
33. Liao B.S., Twiggs L.B., Leung B.S. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet. Gynecol. 67:1986;463.
34. Maeda K., Tsuda H., Hashiguchi Y., Yamamoto K., Inoue T., Ishiko O. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum. Pathol. 33:2002;386-391.
35. Sherman M.E., Bur M.E., Kurman R.J. p53 in endometrial cancer and its putative precursors: evidence for verse pathways of tumorigenesis. Hum. Pathol. 26:1995;1268-1274.
36. Kohler M.F., Nishii H., Humphrey P.A., Sasaki H., Marks J., Bast R.C.et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasia. Am. J. Obstet. Gynecol. 169:1993;690-694.
37. Umpierre S.A., Burke T.W., Tornos C., Ordonez N., Levenback C., Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int. J. Gynecol. Pathol. 13(2):1994;127-130.
38. Nielsen A.L., Nyholm H.C.J. Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: comparison of tumours from patients with and without previous oestrogen therapy. J. Pathol. 171:1993;199-205.
39. Yamauchi N., Sakamoto A., Uozaki H., Iihara K., Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int. J. Gynecol. Pathol. 15:1996;202-208.
40. Carcangiu M.L., Chambers J.T., Voynick I.M., Pirro M., Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma: Part I. Clinical and histologic correlations. Am J. Clin. Pathol. 94:1990;247-254.
41. Halperin R., Zehavi S., Habler L., Hadas E., Bukovsky I., Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur. J. Gynaecol. Oncol. 22:2001;122-126.
42. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 32:2001;567-568.
43. Utaaker E., Iversen O.E., Skaarland E. The distribution and prognostic implications of steroid receptors in endometrial cancer. Gynecol. Oncol. 28:1987;89-100.